Xbrane Biopharma: Q4 2022, Just ahead of launch - Redeye

Redeye slightly adjusts its fair value range of Xbrane on the back of the Q4 report. Considering the significant valuation discount compared to peer biosimilar developers and a year containing high-impact catalysts, we see good prospects for an upside opportunity.

Länk till analysen i sin helhet: https://www.redeye.se/research/881739/xbrane-biopharma-q4-2022-launch-of-ximluci-is-now?utm_source=finwire&utm_medium=RSS